Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
* Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE. * The inhalation solution is designed for targeted lung delivery...
Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE
* For its 30th PCC anniversary, Insilico Medicine nominated ISM0387, the first UAE-based preclinical candidate, jointly announced with the Emirates Drug Establishment (EDE), with the support of local partners including Abu Dhabi Investment Office (ADIO), the Department of Health Abu Dhabi (DoH)...
Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board). The initiative provides scienti...
Insilico Medicine Announces Global R&D Collaboration with Lilly
AI-driven collaboration includes an exclusive worldwide license for a portfolio of programs spanning multiple therapeutic areas. CAMBRIDGE, Mass., March 29, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial in...
Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million
CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co., Limited ("Tenacia"), a commercial-stage biopharmaceutical company dedicated t...
Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women's Health
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. ("ASKA"), a specialized p...
Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery
CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine
("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven
drug discovery company, today announced the launch ofPandaClaw, a
transformative new feature of thePandaOmics
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results for t...
Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previou...
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceuti...
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment ofHalle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Z...
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. * Unlike ISM8969, Insilico's brain-penetrant NLR...
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone payment ofUSD 5 million from Menarini Group after first-in-patient dosing in a Phase 1 trial of MEN2501, highly differentiated small molecule KIF18A inhibitor in d...
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceutical enterprise in China, as well as its subsidiary Shanghai Qilu Pharmaceutical Research Center...
Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor
* Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study inthe United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. * ISM8969 is a novel oral therapeutic candi...
Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines
* New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any causal or frontier LLM * Up to 10x performance gains on key drug discovery benchmarks compared to LLMs that miss the mark on ~75–95% of tasks * Advances Insilico's vision of Pharmaceutical Superint...
Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment
* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insi...
Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"),
a clinical-stage, generative AI-driven drug discovery company, today announced
the completion of first patient first dose in BETHESDA: a Phase IIa clinical
trial of ISM5411 (NCT07265570
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
* Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development. * Under t...
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange
SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on theHong Kong stock m...
